Dermata Therapeutics Inc (DRMA) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Dermata Therapeutics Inc

NASDAQ | DRMA

0.73

USD

+0.00 ( +0.00%)

AT CLOSE (AS OF Jun 6, 2025)

$4.5M

MARKET CAP

P/E Ratio

-1.42

EPS

$3.8

52 Week High

$0.66

52 Week Low

LIFE SCIENCES

Sector

DRMA Chart

Recent Chart

Price Action

Candles

DRMA Technicals

Tags:

DRMA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$13B
Selling General And Administrative	$4.3B
Research And Development	$8.2B
Operating Expenses	$13M
Investment Income Net	-
Net Interest Income	$226K
Interest Income	$226K
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	-
Income Before Tax	-$12B
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	-$12M
Comprehensive Income Net Of Tax	-
Ebit	-
Ebitda	-$12M
Net Income	-$12B

Revenue & Profitability

Earnings Performance

DRMA Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$3.5M
Total Current Assets	$3.5M
Cash And Cash Equivalents At Carrying Value	$3.2M
Cash And Short Term Investments	$3.2M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	-$3.2B
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	$3.2B
Other Current Assets	$372K
Other Non Current Assets	-
Total Liabilities	$2M
Total Current Liabilities	$2M
Current Accounts Payable	$808K
Deferred Revenue	-
Current Debt	-
Short Term Debt	-
Total Non Current Liabilities	$1.2B
Capital Lease Obligations	-
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	-
Other Current Liabilities	$1.2M
Other Non Current Liabilities	-
Total Shareholder Equity	$1.6B
Treasury Stock	-
Retained Earnings	-$66M
Common Stock	$252
Common Stock Shares Outstanding	$1.5M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$11M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	-
Capital Expenditures	$0
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$6.9M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-$828
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$12M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$13B
Selling General And Administrative	$4.3B
Research And Development	$8.2B
Operating Expenses	$13M
Investment Income Net	-
Net Interest Income	$226K
Interest Income	$226K
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	-
Income Before Tax	-$12B
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	-$12M
Comprehensive Income Net Of Tax	-
Ebit	-
Ebitda	-$12M
Net Income	-$12B

DRMA News

DRMA Profile

Dermata Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

None